Results 151 to 160 of about 15,701 (194)

Potential Mechanisms of Sodium-Glucose Cotransporter 2 Inhibitors in Regulating Cardiac and Renal Fibrosis.

Cardiorenal Med
Huang W, Guan T, Yan Z, Cui Y, Bi S, Wu M, Yuan D.   +6 more
europepmc   +1 more source

Targeting NLRP3 Inflammasomes in Myocarditis: Potential Therapeutic Strategies and Clinical Translation. [PDF]

Scientifica (Cairo)
Retnowati FD, Halawa DR, Maayah ZH, Abdallah AM.   +3 more
europepmc   +1 more source

Comparison of SGLT2 Inhibitors for New-Onset Proteinuria Risk in Patients With Type 2 Diabetes and Preserved Kidney Function. [PDF]

Diabetes Obes Metab
Nobayashi H, Satoh M, Hirose T, Nakayama S, Iwabe Y, Hashimoto H, Murakami T, Okada K, Mori T, Metoki H.   +9 more
europepmc   +1 more source

Undifferentiated Purpuric and Desquamative Drug Eruption After Pembrolizumab and Empagliflozin Exposure: A Clinicopathologic Diagnostic Pitfall. [PDF]

Cureus
Biswas N, Khokhar I, Fu JJ.
europepmc   +1 more source

Age-Driven Physiologically Based Pharmacokinetic Modeling of Empagliflozin: Toward Precision Dosing in Youth. [PDF]

ACS Pharmacol Transl Sci
Milhm GP, Moreira FL, Abrahim-Vieira BA.
europepmc   +1 more source

Empagliflozin Attenuates Cardiac Fibrosis by Suppressing Fibroblast-Mediated C-C Motif Chemokine Ligand 2 Expression. [PDF]

J Am Heart Assoc
Nakai E, Horitani K, Ogawa H, Wada K, Yura Y, Min KD, Morioka S, Suwa Y, Shiojima I.   +8 more
europepmc   +1 more source

Eco-friendly second-derivative synchronous fluorescence method for the determination of empagliflozin and sitagliptin in tablets and plasma samples. [PDF]

Sci Rep
Mohamad AAA, Almrasy AA, Abdelazim AH, Taha AS.   +3 more
europepmc   +1 more source

Evaluation of the therapeutic effect of new hypoglycemic drugs on patients with heart failure with reduced ejection fraction and type 2 diabetes: a systematic review and network meta-analysis. [PDF]

Front Cardiovasc Med
Chen XR, Mao XP, Luo D, Yu CQ, Bai JN.
europepmc   +1 more source

Treatment of Youth-Onset Type 2 Diabetes: Focus on SGLT-2 Inhibitor Use. [PDF]

Pediatr Diabetes
Arslanian S, Barrett T, Shehadeh N.
europepmc   +1 more source

Comparing Efficacy and Safety of Different Aldosterone Synthase Inhibitors for Hypertension: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials. [PDF]

Clin Med Insights Cardiol
Hassan Waseem M, Abideen ZU, Shoaib A, Raja HAA, Thada PK, Cheema AH.   +5 more
europepmc   +1 more source